Kailera’s three-pronged obesity shot shows promise in early trial
BioPharma Dive
As Lilly completes the pivotal program for its triple-G drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.
pharminent
May 27, 2026 (Last updated: May 30, 2026)
BioPharma Dive
As Lilly completes the pivotal program for its triple-G drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.
